Logo image of GDS.PA

RAMSAY GENERALE DE SANTE SA (GDS.PA) Stock Fundamental Analysis

EPA:GDS - Euronext Paris - Matif - FR0000044471 - Common Stock - Currency: EUR

10.4  +0.1 (+0.97%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to GDS. GDS was compared to 23 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of GDS have multiple concerns. GDS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

In the past year GDS has reported negative net income.
GDS had a positive operating cash flow in the past year.
GDS had positive earnings in 4 of the past 5 years.
In the past 5 years GDS always reported a positive cash flow from operatings.
GDS.PA Yearly Net Income VS EBIT VS OCF VS FCFGDS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

GDS's Return On Assets of -0.83% is on the low side compared to the rest of the industry. GDS is outperformed by 84.62% of its industry peers.
GDS has a worse Return On Equity (-4.78%) than 84.62% of its industry peers.
GDS has a worse Return On Invested Capital (1.78%) than 76.92% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for GDS is below the industry average of 5.35%.
The last Return On Invested Capital (1.78%) for GDS is above the 3 year average (1.33%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -0.83%
ROE -4.78%
ROIC 1.78%
ROA(3y)0.56%
ROA(5y)0.57%
ROE(3y)3.07%
ROE(5y)3.32%
ROIC(3y)1.33%
ROIC(5y)1.08%
GDS.PA Yearly ROA, ROE, ROICGDS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 10

1.3 Margins

Looking at the Operating Margin, with a value of 2.48%, GDS is doing worse than 73.08% of the companies in the same industry.
In the last couple of years the Operating Margin of GDS has declined.
With an excellent Gross Margin value of 78.75%, GDS belongs to the best of the industry, outperforming 80.77% of the companies in the same industry.
GDS's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 2.48%
PM (TTM) N/A
GM 78.75%
OM growth 3Y24.12%
OM growth 5Y-11.7%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.38%
GM growth 5Y-0.57%
GDS.PA Yearly Profit, Operating, Gross MarginsGDS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

2

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so GDS is destroying value.
The number of shares outstanding for GDS remains at a similar level compared to 1 year ago.
GDS has about the same amout of shares outstanding than it did 5 years ago.
Compared to 1 year ago, GDS has an improved debt to assets ratio.
GDS.PA Yearly Shares OutstandingGDS.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
GDS.PA Yearly Total Debt VS Total AssetsGDS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

GDS has an Altman-Z score of 1.01. This is a bad value and indicates that GDS is not financially healthy and even has some risk of bankruptcy.
GDS has a Altman-Z score (1.01) which is comparable to the rest of the industry.
GDS has a debt to FCF ratio of 8.96. This is a slightly negative value and a sign of low solvency as GDS would need 8.96 years to pay back of all of its debts.
GDS has a Debt to FCF ratio of 8.96. This is comparable to the rest of the industry: GDS outperforms 42.31% of its industry peers.
GDS has a Debt/Equity ratio of 3.23. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 3.23, GDS is doing worse than 80.77% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 3.23
Debt/FCF 8.96
Altman-Z 1.01
ROIC/WACC0.37
WACC4.74%
GDS.PA Yearly LT Debt VS Equity VS FCFGDS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.3 Liquidity

GDS has a Current Ratio of 0.81. This is a bad value and indicates that GDS is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of GDS (0.81) is comparable to the rest of the industry.
A Quick Ratio of 0.72 indicates that GDS may have some problems paying its short term obligations.
GDS has a Quick ratio of 0.72. This is comparable to the rest of the industry: GDS outperforms 57.69% of its industry peers.
Industry RankSector Rank
Current Ratio 0.81
Quick Ratio 0.72
GDS.PA Yearly Current Assets VS Current LiabilitesGDS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2

3. Growth

3.1 Past

The earnings per share for GDS have decreased strongly by -209.12% in the last year.
The Revenue has been growing slightly by 6.49% in the past year.
Measured over the past years, GDS shows a quite strong growth in Revenue. The Revenue has been growing by 8.04% on average per year.
EPS 1Y (TTM)-209.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-143.75%
Revenue 1Y (TTM)6.49%
Revenue growth 3Y7.57%
Revenue growth 5Y8.04%
Sales Q2Q%5.78%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GDS.PA Yearly Revenue VS EstimatesGDS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B
GDS.PA Yearly EPS VS EstimatesGDS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0.1 0.2 0.3 0.4 0.5

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GDS. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GDS.PA Price Earnings VS Forward Price EarningsGDS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, GDS is valued a bit cheaper than 73.08% of the companies in the same industry.
GDS's Price/Free Cash Flow ratio is rather cheap when compared to the industry. GDS is cheaper than 92.31% of the companies in the same industry.
Industry RankSector Rank
P/FCF 2.61
EV/EBITDA 8.69
GDS.PA Per share dataGDS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 30 40

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

GDS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

RAMSAY GENERALE DE SANTE SA

EPA:GDS (3/7/2025, 7:00:00 PM)

10.4

+0.1 (+0.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-27 2025-02-27
Earnings (Next)08-28 2025-08-28
Inst Owners39.92%
Inst Owner ChangeN/A
Ins Owners6.59%
Ins Owner ChangeN/A
Market Cap1.15B
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.23
P/FCF 2.61
P/OCF 1.89
P/B 1.02
P/tB N/A
EV/EBITDA 8.69
EPS(TTM)-0.49
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)3.99
FCFY38.33%
OCF(TTM)5.5
OCFY52.92%
SpS45.35
BVpS10.21
TBVpS-10.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.83%
ROE -4.78%
ROCE 2.44%
ROIC 1.78%
ROICexc 1.84%
ROICexgc 3.43%
OM 2.48%
PM (TTM) N/A
GM 78.75%
FCFM 8.79%
ROA(3y)0.56%
ROA(5y)0.57%
ROE(3y)3.07%
ROE(5y)3.32%
ROIC(3y)1.33%
ROIC(5y)1.08%
ROICexc(3y)1.41%
ROICexc(5y)1.17%
ROICexgc(3y)2.61%
ROICexgc(5y)2.14%
ROCE(3y)1.82%
ROCE(5y)1.48%
ROICexcg growth 3Y32.93%
ROICexcg growth 5Y-19.53%
ROICexc growth 3Y30.51%
ROICexc growth 5Y-13.14%
OM growth 3Y24.12%
OM growth 5Y-11.7%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.38%
GM growth 5Y-0.57%
F-Score4
Asset Turnover0.77
Health
Industry RankSector Rank
Debt/Equity 3.23
Debt/FCF 8.96
Debt/EBITDA 6.46
Cap/Depr 38.17%
Cap/Sales 3.35%
Interest Coverage 0.61
Cash Conversion 107.94%
Profit Quality N/A
Current Ratio 0.81
Quick Ratio 0.72
Altman-Z 1.01
F-Score4
WACC4.74%
ROIC/WACC0.37
Cap/Depr(3y)44.5%
Cap/Depr(5y)45.51%
Cap/Sales(3y)3.84%
Cap/Sales(5y)4.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-209.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-143.75%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)6.49%
Revenue growth 3Y7.57%
Revenue growth 5Y8.04%
Sales Q2Q%5.78%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y29.03%
EBIT growth 3Y33.51%
EBIT growth 5Y-4.6%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y79.01%
FCF growth 3Y-4.21%
FCF growth 5Y63.68%
OCF growth 1Y43.86%
OCF growth 3Y-3.47%
OCF growth 5Y22.4%